FRANKLIN LAKES, N.J., June 12, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the worldwide commercial launch of a new automated instrument that prepares samples for clinical diagnostics using flow cytometry, enabling a complete "walkaway" workflow solution designed to improve standardization and reproducibility in cellular diagnostics.
The BD FACSDuet™ Premium Sample Preparation System leverages liquid-handling robotics to automate the entire sample preparation process, for both in vitro diagnostics (IVD) and user-defined tests, including cocktailing, washing and centrifuging – and then automatically transfers samples to the physically integrated BD FACSLyric™ Clinical Flow Cytometry System, without human interaction. By being integrated with the flow cytometer, the BD FACSDuet™ Premium System enables a "walkaway" workflow solution that requires fewer manual steps, fewer resources and less user hands-on time than previous solutions.
Flow cytometry is an essential tool for clinical diagnostics, commonly utilized in the diagnosis and management of diseases like cancer.
"Our clinical customers have long trusted BD and our best-in-class products to standardize every step of the clinical lab workflow – from panel creation to sample preparation to analysis to report," said Steve Conly, worldwide president, BD Biosciences. "The flagship BD FACSLyric™ Flow Cytometry System is one of the fastest adopted clinical instruments in the world and now together with the FACSDuet™ Premium System, which has achieved IVD status in the U.S. and Europe, we usher in greater levels of automation so that our customers can focus more of their valuable time on analyzing and interpreting samples and impacting outcomes."
The BD FACSDuet™ Premium System is now available to order through local sales representatives. More information is available at bdbiosciences.com and in the recent BD Biosciences Power of Automation Keynote Presentation.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health™ by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.
Contacts: | |
Media: | Investors: |
Troy Kirkpatrick | Francesca DeMartino |
VP, Public Relations | SVP, Head of Investor Relations |
858.617.2361 | 201.847.5743 |
This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
Last Trade: | US$225.15 |
Daily Change: | -2.02 -0.89 |
Daily Volume: | 1,682,996 |
Market Cap: | US$65.080B |
November 07, 2024 October 30, 2024 October 29, 2024 October 14, 2024 September 26, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB